Clinical Management of Elderly Patients with Type 2 Diabetes Mellitus

References

• . American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51( 5 suppl guidelines):S265–S280
   PubMed Web of Science ®Google Scholar
• . Vischer UM, Bauduceau B, Bourdel–Marchasson I,; Alfediam/SFGG French-speaking group for study of diabetes in the elderly. A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes Metab. 2009;35(3):168–177
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed September 28, 2011
   Google Scholar
• . Arias E. United States life tables, 2006. National Vital Statistics Reports; vol 58, no 21. National Center for Health Statistics. http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf. Accessed August 8, 2011
   Google Scholar
• . Hobbs FB. Population profile of the United States: the elderly population. U.S. Census Bureau. http://www.census.gov/population/www/pop-profile/elderpop.html. Accessed September 28, 2011
   Google Scholar
• . Narayan KM, Boyle JP, Geiss LS,. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care. 2006;29(9):2114–2116
   PubMed Web of Science ®Google Scholar
• . Pleis JR, Lucas JW, Ward B W. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. Vital Health Stat 10. 2009; 242:1–157
   Google Scholar
• . Volpato S, Maraldi C, Fellin R. Type 2 diabetes and risk for functional decline and disability in older persons. Curr Diabetes Rev. 2010;6(3): 134–143
   PubMedGoogle Scholar
• . Zhang X, Decker FH, Luo H,. Trends in the prevalence and comorbidities of diabetes mellitus in nursing home residents in the United States: 1995–2004. J Am Geriatr Soc. 2010;58(4):724–730
   PubMed Web of Science ®Google Scholar
• . Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21(7):1138–1145
   PubMed Web of Science ®Google Scholar
• . Franco OH, Steyerberg EW, Hu FB,. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145–1151
   PubMedGoogle Scholar
• . American Diabetes Association. Economic cost of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596–615
   PubMed Web of Science ®Google Scholar
• . Agency for Healthcare Research and Quality. Economic and health costs of diabetes: HCUP highlight 1. AHRQ publication no. 05-0034. Agency for Healthcare Research and Quality. http://www.ahrq.gov/data/hcup/highlight1/high1.htm. Accessed August 10, 2011
   Google Scholar
• . Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab. 2005;31(spec no 2): 5S27–5S34
   PubMedGoogle Scholar
• . Shimizu M, Kawazu S, Tomono S,. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance. Diabetes Care. 1996;19(1):8–11
   PubMed Web of Science ®Google Scholar
• . Iozzo P, Beck–Nielsen H, Laakso M, Smith U, Yki–Järvinen H, Ferrannini E. Independent Influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab. 1999;84(3):863–868
   PubMed Web of Science ®Google Scholar
• . Thearle M, Brillantes AM. Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity. Curr Opin Clin Nutr Metab Care. 2005; 8(1):9–16
   PubMed Web of Science ®Google Scholar
• . Yates AP, Laing I. Age-related increase in haemoglobin A1c and fasting plasma glucose is accompanied by a decrease in beta cell function without change in insulin sensitivity: evidence from a cross-sectional study of hospital personnel. Diabet Med. 2002;19(3):254–258
   PubMed Web of Science ®Google Scholar
• . Chiu KC, Lee NP, Cohan PC, Chuang LM. Beta cell function declines with age in glucose tolerant Caucasians. Clin Endocrinol (Oxf). 2000; 53(5):569–575
   PubMed Web of Science ®Google Scholar
• . Novelli M, De Tata V, Bombara M,. Age-dependent reduction in GLUT-2 levels is correlated with the impairment of the insulin secretory response in isolated islets of Sprague-Dawley rats. Exp Gerontol. 2000;35(5):641–651
   PubMed Web of Science ®Google Scholar
• . Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284(1):E7–E12
   PubMed Web of Science ®Google Scholar
• . Cnop M, Grupping A, Hoorens A,. Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol. 2000;156(1):237–244
   PubMed Web of Science ®Google Scholar
• . Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev. 2008;29(3):303–316
   PubMed Web of Science ®Google Scholar
• . Butler AE, Janson J, Bonner–Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110
   PubMed Web of Science ®Google Scholar
• . Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25(11):913–925
   PubMed Web of Science ®Google Scholar
• . Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009; 7(6):324–342
   PubMedGoogle Scholar
• . Biggs ML, Mukamal KJ, Luchsinger JA,. Association between adiposity in midlife and older age and risk of diabetes in older adults. JAMA. 2010;303(24):2504–2512
   PubMed Web of Science ®Google Scholar
• . Hyde Z, Flicker L, Almeida OP,. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab. 2010;95(7):3165–3172
   PubMed Web of Science ®Google Scholar
• . Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269–2276
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Diabetes data and trends. US Department of Health and Human Services. http://apps.nccd.cdc.gov/DDTSTRS/default.aspx. Accessed September 28, 2011
   Google Scholar
• . Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care. 2003;26(7):2075–2080
   PubMed Web of Science ®Google Scholar
• . Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Diabetes Care. 2010;33(5):1055–1060
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO,. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a Scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357
   PubMed Web of Science ®Google Scholar
• . Huang ES, Liu JY, Moffet HH,. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34(6):1329–1336
   PubMed Web of Science ®Google Scholar
• . European Diabetes Working Party for Older People. Clinical guidelines for type 2 diabetes mellitus. International Academy Nutrition and Aging and European Union Geriatric Medicine Society. http://instituteofdiabetes.org/wp-content/themes/IDOP/other/diabetes_guidelines_for_older_people.pdf. Accessed August 2, 2011
   Google Scholar
• . Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32( suppl 1):S1–S201
   Web of Science ®Google Scholar
• . Zettervall DK. Management of the patient with advanced complications, functional decline, and persistent hyperglycemia. Consult Pharm. 2010;25( suppl B):5–10
   PubMedGoogle Scholar
• . Fung V, Mangione CM, Huang J,. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45(2):355–375
   PubMed Web of Science ®Google Scholar
• . MacDonald MR, Eurich DT, Majumdar SR,. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. 2010;33(6):1213–1218
   PubMed Web of Science ®Google Scholar
• . Tanwani LK. Insulin therapy in the elderly patient with diabetes. Am J Geriatr Pharmacother. 2011;9(1):24–36
   PubMedGoogle Scholar
• . Zafon C, Creus C. A comparison on insulin regimen treatment of elderly (> 70 years) and younger (< 70 years) type 2 diabetic patients in actual clinical practice [published online ahead of print May 6, 2011]. Acta Diabetol
   Google Scholar
• . Lipscombe LL, Gomes T, Lévesque LE,. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298(22):2634–2643
   PubMed Web of Science ®Google Scholar
• . Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008; 168(21):2368–2375
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Zinman B, Lachin JM,; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–851
   PubMed Web of Science ®Google Scholar
• . Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168(8):820–825
   PubMed Web of Science ®Google Scholar
• . Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1): 32–39
   PubMed Web of Science ®Google Scholar
• . Amylin Pharmaceuticals Inc. BYETTA (exenatide) injection [package insert]. http://pi.lilly.com/us/byetta-pi.pdf. Accessed September 28, 2011
   Google Scholar
• . Linnebjerg H, Kothare PA, Seger M,. Exenatide—pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with type 2 diabetes. Int J Clin Pharmacol Ther. 2011;49(2):99–108
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brandle M,. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K,; LEAD-2 Study Group. Effi cacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Russell–Jones D, Vaag A, Schmitz O,. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse JB,; LEAD-4 Study Investigators. efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32(7):1224–1230
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R,. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Novo Nordisk Inc. Victoza® (liraglutide [rDNA origin] injection) [package insert]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf. Accessed August 2, 2011
   Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Merck and Co Inc. Januvia (sitagliptin) tablets [package insert]. Merck Sharp and Dohme Corp. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed September 28, 2011
   Google Scholar
• . Boehringer Ingelheim Pharmaceuticals Inc. Tradjenta (linagliptin) tablets [package insert]. http://hcp.tradjenta.com/prescribinginformation.jsp. Accessed September 28, 2011
   Google Scholar
• . Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57(11):2011–2019
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Rosenstock J, Pi–Sunyer FX,. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017–3022
   PubMed Web of Science ®Google Scholar
• . Doucet J, Chacra A, Maheux P,. efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27(4):863–869
   PubMed Web of Science ®Google Scholar
• . Bristol-Myers Squibb Company. Onglyza (saxagliptin) tablets [package insert]. Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP. http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed September 28, 2011
   Google Scholar
• . Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804–812
   PubMed Web of Science ®Google Scholar
• . Barzilai N, Guo H, Mahoney EM,. efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–1058
   PubMed Web of Science ®Google Scholar
• . Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12(5):384–392
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB,; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar